Get in touch
Our platform

AI and gene editing, working together.

Two proprietary platforms make our therapies more precise and far more affordable.

Software
ImmunoAI
Our AI platform optimises the entire TCR-T pipeline, from target discovery to manufacturing, making therapies faster to develop and dramatically cheaper to produce.
Biology
CRISPR platform
Our own gene-editing platform precisely writes tumour-specific receptors into T cells, the foundation of every Lonabio therapy.
Pipeline

Starting with blood cancers. Solid tumours next.

In the clinic
Leukemia
Our lead programmes target leukemia, with clinical trials underway.
In the clinic
Lymphoma
TCR-T therapies for lymphoma are advancing through clinical trials.
Next
Solid tumours
Extending our approach to solid tumours, the next frontier in TCR-T.
Clinical trials in progress
Trials are underway, with active labs in London and Suzhou and patient recruitment expanding to Singapore. More to share shortly.